Abbott Laboratories $ABT Shares Purchased by Mariner LLC

Mariner LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 40.4% during the third quarter, HoldingsChannel.com reports. The fund owned 1,893,420 shares of the healthcare product maker’s stock after acquiring an additional 544,866 shares during the period. Mariner LLC’s holdings in Abbott Laboratories were worth $253,596,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories during the third quarter valued at $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories in the 3rd quarter valued at about $31,000. Anfield Capital Management LLC boosted its stake in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares during the period. Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories during the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the 3rd quarter worth about $33,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Up 1.8%

NYSE:ABT opened at $109.93 on Tuesday. The stock has a fifty day simple moving average of $114.25 and a 200 day simple moving average of $123.65. The firm has a market capitalization of $191.03 billion, a price-to-earnings ratio of 29.55, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Sanford C. Bernstein lowered their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Barclays reduced their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Finally, The Goldman Sachs Group cut their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 3,055 shares of company stock worth $353,097. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.